Compare SOLS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOLS | ABVX |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.0B |
| IPO Year | N/A | N/A |
| Metric | SOLS | ABVX |
|---|---|---|
| Price | $52.26 | $114.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $54.00 | ★ $118.33 |
| AVG Volume (30 Days) | ★ 3.8M | 1.9M |
| Earning Date | 02-11-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,812,000,000.00 | $6,231,374.00 |
| Revenue This Year | $3.34 | $6.80 |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $25.08 | ★ N/A |
| Revenue Growth | ★ 4.47 | N/A |
| 52 Week Low | $40.43 | $4.77 |
| 52 Week High | $61.00 | $148.83 |
| Indicator | SOLS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.25 |
| Support Level | N/A | $116.20 |
| Resistance Level | N/A | $129.56 |
| Average True Range (ATR) | 0.00 | 7.87 |
| MACD | 0.00 | -2.47 |
| Stochastic Oscillator | 0.00 | 15.05 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.